drugset / Trial / NCT05870475
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
RandomizedParallel-groupOpen-labelTreatment
Summary
Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
Timeline
- Start
- 2023-06-30
- Primary completion
- 2028-03-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |